Image

Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients After Metabolic and Bariatric Surgery

Direct Measurement of Ingestive Behaviour in Relation to Sex Differences and Gastrointestinal Hormone Levels in Patients After Metabolic and Bariatric Surgery

Recruiting
18 years and older
All
Phase N/A

Powered by AI

Overview

Bariatric surgery (BS), especially procedures like Sleeve Gastrectomy (SG) and Roux-en-Y gastric bypass (RYGB), is the most effective treatment for obesity. Yet, the exact mechanisms governing its effect are somewhat elusive, with current research mainly focusing on post-operative food intake outcomes based on self-reported data, which might not fully capture the nuanced changes in eating behaviours.

To address these gaps, our study plans to employ the newly developed "drinkometer", a device capable of analysing the intricate changes in drinking behaviour following BS. This tool promises to bring a more detailed perspective to the changes in ingestive behaviours, bypassing the inaccuracies of self-reporting methods. By expanding our research to encompass diverse patient demographics and examining potential links to physiological shifts like gut hormone level alterations, the study aims to provide a more rounded understanding of the long-term impacts of BS on eating behaviours.

Description

HYPOTHESIS AND PRIMARY OBJECTIVE

So far, studies of ingestive behaviour in humans have produced ambiguous results. Moreover, direct measurements of ingestive behaviour in humans after BS are still rare and the roles of sex and gut hormones, as well as their relevance for clinical outcome parameters, such as body weight loss, remain elusive. A comprehensive understanding of how a given intervention such as BS affects food intake requires a detailed analysis of the ingestive behaviour itself, not simply the measurement of the outcome of the behaviour. In other words, the information on how the food is consumed is equally or even more important than the information on how much food has been ingested.

This study employs the drinkometer methodology to perform direct measurements of ingestive behaviour in male and female human patients after SG and RYGB along with parallel measurements of postprandial gut hormone levels. Furthermore, this study investigates the clinical relevance of changes in ingestive behaviour by correlating microstructural parameters with body weight loss in a consecutive set of patients who received RYGB at the University Hospital Zurich five years before the time of recruitment.

Of note, the proposed experiments aim to test specific hypotheses regarding the behavioural mechanisms underlying potential changes in food intake after BS in humans. Thus, this research do not aim to identify how BS affects one or the other single microstructural parameters of eating or drinking. Instead, this study investigates how a given intervention that is known to substantially affect food intake behaviour - such as BS - alters the profile of a group of microstructural parameters of ingestive behaviour in humans. Given that ingestive behaviour represents the readout of the central nervous system mechanisms controlling energy intake (e.g., palatability, aversion, avoidance, satiation), the results of the proposed studies will inform the search for the underlying neural circuits in the brain that are specifically altered by BS. If there is no altered behaviour, there would be no point in investigating the underlying physiology. More specifically, this study aims to:

  1. Investigate longitudinal changes and differences in the ingestive behaviour of female patients before and within one year after either primary RYGB or primary SG (Study 1).
  2. Investigate a possible association between the ingestive behaviour and the prandial gut hormone levels of female patients before and within one year after either primary RYGB or SG (Study 1).
  3. Investigate a possible difference between the ingestive behaviour of female and male patients before and within one year after primary RYGB (Study 2).
  4. Investigate a possible association between the postoperatively achieved body weight loss of female and male patients 5 years after primary RYGB and ingestive behaviour (Study 3).
  5. Investigate, in a subset of responders and non-responders to primary RYGB, a possible association between postprandial gut hormone levels of female and male patients 5 years after primary RYGB and ingestive behaviour (Study 3).

PRIMARY AND SECONDARY ENDPOINTS

In the research protocol, the primary and secondary outcomes specific to each of the three studies planned within the research project have been described. Recognising that each study has its unique objectives and hypotheses, the outcomes have been specified distinctly for each study to ensure clarity and focus in the research approach.

For each of the three studies, the primary outcomes are those key results that the study is primarily designed to assess. These are the main effects or findings that are anticipated to provide the most significant insights into the research questions. Secondary outcomes, while still important, are additional results that can be explored after answering the main research questions. These might provide supplementary information, support the primary outcomes, or offer insights into other areas related to the main research question.

By presenting these outcomes separately for each study, this study aims to provide a structured and transparent overview of the research intentions, allowing for a clear understanding of the objectives and measures in each specific part of the project. This approach not only aids in maintaining the focus and integrity of each study but also assists in the clear communication of the research goals and methods.

PROJECT DESIGN

The proposed studies will test key elements of ingestive behaviour and their relation to pre- and postprandial levels of gut hormones as well as sex differences after the two most frequently performed bariatric operations. They will thus provide useful information for planning and conducting future trials in the field, such as optimal recruitment and retention strategies, intervention delivery, data collection methods and adherence to study protocols. The proposed studies will further provide empirical estimates of effect sizes of bariatric surgery and long-term associations of ingestive behaviour with gut hormones for post-bariatric body weight loss. The potential outcomes of Studies 1, 2 and 3 are conceptually different. Nevertheless, the results of these studies will complement each other as well as our findings from previous studies, and can be used to calculate sample sizes for future trials.

Eligibility

Inclusion Criteria:

  • Age ≥ 18 year
  • BMI ≥ 35 kg/m2 for patients with planned RYGB or SG operation
  • BMI ≥ 30 kg/m2 for external controls affected by obesity but no planned RYGB or SG within the next 12 months, and
  • BMI ≥ 18.5 kg/m2 and ≤ 24.9 kg/m2 for controls without obesity.

Exclusion Criteria:

  • history of previous bariatric operations and/ or revisional surgery (e.g., alteration of limb lengths after primary RYGB),
  • smoking,
  • established diagnosis of type 1 or 2 diabetes mellitus, and
  • polycystic ovary syndrome (PCOS).

Study details
    Obesity

NCT06538948

University of Zurich

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.